120 related articles for article (PubMed ID: 38016110)
1. One Mutation to Rule Them All: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling.
Müller S; Krishnamurty AT
Cancer Res; 2024 Jan; 84(1):6-8. PubMed ID: 38016110
[TBL] [Abstract][Full Text] [Related]
2. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression.
Hsu WH; LaBella KA; Lin Y; Xu P; Lee R; Hsieh CE; Yang L; Zhou A; Blecher JM; Wu CJ; Lin K; Shang X; Jiang S; Spring DJ; Xia Y; Chen P; Shen JP; Kopetz S; DePinho RA
Cancer Discov; 2023 Dec; 13(12):2652-2673. PubMed ID: 37768068
[TBL] [Abstract][Full Text] [Related]
4. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.
Bartolini A; Cardaci S; Lamba S; Oddo D; Marchiò C; Cassoni P; Amoreo CA; Corti G; Testori A; Bussolino F; Pasqualini R; Arap W; Corà D; Di Nicolantonio F; Marchiò S
Clin Cancer Res; 2016 Oct; 22(19):4923-4933. PubMed ID: 27143691
[TBL] [Abstract][Full Text] [Related]
5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
7. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
8. Integrated multi-omics characterization of KRAS mutant colorectal cancer.
Chong W; Zhu X; Ren H; Ye C; Xu K; Wang Z; Jia S; Shang L; Li L; Chen H
Theranostics; 2022; 12(11):5138-5154. PubMed ID: 35836817
[TBL] [Abstract][Full Text] [Related]
9. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers.
Liu X; Xu X; Wu Z; Shan Q; Wang Z; Wu Z; Ding X; Huang W; Wang Z
Front Immunol; 2022; 13():961350. PubMed ID: 36172359
[TBL] [Abstract][Full Text] [Related]
10. Liver Endothelium Promotes HER3-Mediated Cell Survival in Colorectal Cancer with Wild-Type and Mutant KRAS.
Rathore M; Zhang W; Wright M; Bhattacharya R; Fan F; Vaziri-Gohar A; Winter J; Wang Z; Markowitz SD; Willis J; Ellis LM; Wang R
Mol Cancer Res; 2022 Jun; 20(6):996-1008. PubMed ID: 35276002
[TBL] [Abstract][Full Text] [Related]
11. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
Moss DY; McCann C; Kerr EM
Sci Signal; 2022 Oct; 15(756):eabj3490. PubMed ID: 36256706
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression.
Lin CC; Kuo IY; Wu LT; Kuan WH; Liao SY; Jen J; Yang YE; Tang CW; Chen YR; Wang YC
Theranostics; 2020; 10(22):10001-10015. PubMed ID: 32929330
[TBL] [Abstract][Full Text] [Related]
13. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo.
Najumudeen AK; Fey SK; Millett LM; Ford CA; Gilroy K; Gunduz N; Ridgway RA; Anderson E; Strathdee D; Clark W; Nixon C; Morton JP; Campbell AD; Sansom OJ
Nat Commun; 2024 Jan; 15(1):100. PubMed ID: 38168062
[TBL] [Abstract][Full Text] [Related]
14. Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis.
Dias Carvalho P; Martins F; Mendonça S; Ribeiro A; Machado AL; Carvalho J; Oliveira MJ; Velho S
Int J Cancer; 2022 Nov; 151(10):1810-1823. PubMed ID: 35869872
[TBL] [Abstract][Full Text] [Related]
15. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
16. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
[TBL] [Abstract][Full Text] [Related]
17. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
18. Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance.
Pelullo M; Nardozza F; Zema S; Quaranta R; Nicoletti C; Besharat ZM; Felli MP; Cerbelli B; d'Amati G; Palermo R; Capalbo C; Talora C; Di Marcotullio L; Giannini G; Checquolo S; Screpanti I; Bellavia D
Cancer Res; 2019 Nov; 79(21):5575-5586. PubMed ID: 31506332
[TBL] [Abstract][Full Text] [Related]
19. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer.
Zhou Q; Peng Y; Ji F; Chen H; Kang W; Chan LS; Gou H; Lin Y; Huang P; Chen D; Wei Q; Su H; Liang C; Zhang X; Yu J; Wong CC
Nat Commun; 2023 Aug; 14(1):4677. PubMed ID: 37542037
[TBL] [Abstract][Full Text] [Related]
20. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
